Organogenesis ORGO 深 沪
已收盘 08-14 16:00:00 美东时间
1.79
+0.030
+1.70%
华盛通- 最 高1.81
- 今 开1.76
- 成交量 54.76万股
- 最 低 1.72
- 昨 收 1.76
- 总市值 2.30亿
- 52周最高 7.0771
- 市盈率 静 11.65
- 换手率 0.00%
- 52周最低 1.54
- 委 比 -21.57%
- 总股本 1.29亿
- 历史最高 310.90
- 量 比 0.32
- 振 幅 5.11%
- 历史最低 1.54
- 每 手 1
- 风险率 1.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2
Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.
08-07 21:24
Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket
Shares of Atlassian Corp (NASDAQ:TEAM) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Atlassian reported fourth-quarter revenue of $1.766 billion, up 28% year-over-year. The revenue total beat a Street consensus estimate of $1.660...
08-07 16:33
Organogenesis Launches New $75 Million At-The-Market Offering
Organogenesis Holdings ( ($ORGO) ) just unveiled an announcement. On August 6, ...
08-07 05:52
Organogenesis 2026年第二季度财报：产品收入下降58%，年度指引下调
Organogenesis 2026年第二季度总营收4,375.5万美元，稀释每股亏损0.77美元，净产品收入同比下降58%；毛利率降至45%，公司将全年净收入指引更新至1.79亿至2.15亿美元。
08-07 01:18
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE:DHR) fell sharply in pre-market trading following second-quarter results. Danaher posted second-quarter adjusted EPS of $1.94, beating market estimates of $1.83. The...
07-21 20:01
Organogenesis' Biologics License Application For ReNu Receives FDA's Acceptance For Review To Treat Pain In Symptomatic Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing determination and accepte...
07-07 04:06
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
Organogenesis Holdings Inc. announced that the FDA has accepted its Biologics License Application (BLA) for ReNu®, a cryopreserved amniotic suspension allograft for treating knee osteoarthritis pain, with a PDUFA target action date set for April 24, 2027. ReNu® has been studied in three large RCTs involving over 1,300 patients and received FDA RMAT designation in 2021. The company aims to bring the first non-surgical biologic therapy to millions ...
07-06 20:05
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Deckers Outdoor, UP Fintech And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures rise with Dow gaining 300 points. Deckers Outdoor Corp shares fall after beating Q4 revenue estimates and providing fiscal 2027 guidance.
05-22 20:38
